CLDX HealthcareBeta data

Celldex Therapeutics, Inc.

$29.71+2.31%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.3B USD
Enterprise value: 1.6B USD
Full-time employees: 198

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #1,055 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 66% from December 2022 to July 2026.
Celldex Therapeutics had 66% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Celldex Therapeutics had 66% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Operating margin at a 6-year low. -18600% in 2025, the weakest of the last 6 years.
Celldex Therapeutics's operating margin fell to -18600% in 2025, its lowest in the 6 years of filings we have.
Stock-based pay is a large cost. Stock pay was 2344% of revenue in 2025.
Celldex Therapeutics paid employees $36M in stock in 2025, 2344% of its $2M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Investment surge. Capital spending 176% of revenue, up from 78% in 2022.
Celldex Therapeutics is spending 176% of revenue on facilities and equipment, up from 78% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

StockQuotient Score

25/ 100▼ 1 since Oct 27 close

Oct 5 26 → Nov 4 25 (-1)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-14.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-19.9%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-10.4%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield30.6%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

0/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

12-month revenue fell 81.7%

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth-63.5%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-97.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

4/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-206220.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-38.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-38.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.31Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-43.9%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.90

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.80Sector median: 0.6250 · MAD: 0.3380

Current ratio11.82×

Yahoo FinanceReported value33% base weight · Z-score 6.67Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

Yahoo FinanceReported value33% base weight · Z-score 1.05Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Celldex Therapeutics

Is Celldex Therapeutics getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 81.7%. Its overall score is 25/100, down 1 since Oct 28, 2026.
How is Celldex Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -14.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -14.6% vs peers 1.5% (weaker than 100% of peers).
Is Celldex Therapeutics growing?: More slowly than most of its peers. Growth scores 0/100 against 1,393 healthcare peers. 3-year revenue growth -63.5% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -63.5% vs peers 5.8% (weaker than 100% of peers).
How profitable is Celldex Therapeutics?: Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -206220.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -206220.3% vs peers 7.1% (weaker than 100% of peers).
How risky is Celldex Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 91% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 91% of peers). Beta 0.90 vs a peer median of 0.63 (weaker than 66% of peers).Beta 0.90 vs peers 0.63 (weaker than 66% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 81.7%

Worth watching: Celldex Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	865,000 USD	158,000 USD	−81.7%
Net income (12 months)	−283.6M USD	−300.5M USD	+6.0%
Operating margin	-35729.8%	-206220.3%	−170490.4 pts
Free cash flow (12 months)	−226.2M USD	−242.1M USD	+7.0%
Cash	35.7M USD	47.5M USD	+32.8%
Shares outstanding	78.5M	78.5M	+0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	97.8%	95.8%	95.6%	97.2%	87.1%	▼ 10 pts
Operating margin	-1531.8%	-4889.0%	-2245.3%	-2778.9%	-18599.8%	▼ >999 pts
Net margin	—	—	-2054.8%	-2248.8%	-16748.0%	▼ >999 pts
Return on assets (ROA)	—	—	-30.4%	-19.9%	-44.4%	▼ 24 pts
Return on equity (ROE)	—	—	-33.0%	-21.1%	-49.1%	▼ 28 pts
Free cash flow margin	-1336.4%	-4478.6%	-1585.2%	-2274.9%	-13829.1%	▼ >999 pts
Current ratio	24.86×	17.07×	13.87×	18.91×	10.49×	▼ 45%

CLDX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #1,055 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 66% from December 2022 to July 2026.

Celldex Therapeutics had 66% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Celldex Therapeutics had 66% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Operating margin at a 6-year low. -18600% in 2025, the weakest of the last 6 years.

Celldex Therapeutics's operating margin fell to -18600% in 2025, its lowest in the 6 years of filings we have.

Stock-based pay is a large cost. Stock pay was 2344% of revenue in 2025.

Celldex Therapeutics paid employees $36M in stock in 2025, 2344% of its $2M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Investment surge. Capital spending 176% of revenue, up from 78% in 2022.

Celldex Therapeutics is spending 176% of revenue on facilities and equipment, up from 78% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Questions investors ask about Celldex Therapeutics

Is Celldex Therapeutics getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 81.7%. Its overall score is 25/100, down 1 since Oct 28, 2026.

How is Celldex Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -14.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -14.6% vs peers 1.5% (weaker than 100% of peers).

Is Celldex Therapeutics growing?

More slowly than most of its peers. Growth scores 0/100 against 1,393 healthcare peers. 3-year revenue growth -63.5% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -63.5% vs peers 5.8% (weaker than 100% of peers).

How profitable is Celldex Therapeutics?

Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -206220.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -206220.3% vs peers 7.1% (weaker than 100% of peers).

How risky is Celldex Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 91% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 91% of peers). Beta 0.90 vs a peer median of 0.63 (weaker than 66% of peers).Beta 0.90 vs peers 0.63 (weaker than 66% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

865,000 USD

158,000 USD

−81.7%

Net income (12 months)

−283.6M USD

−300.5M USD

+6.0%

Operating margin

-35729.8%

-206220.3%

−170490.4 pts

Free cash flow (12 months)

−226.2M USD

−242.1M USD

+7.0%

Cash

35.7M USD

47.5M USD

+32.8%

Shares outstanding

78.5M

78.5M

+0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

97.8%

95.8%

95.6%

97.2%

87.1%

▼ 10 pts

Operating margin

-1531.8%

-4889.0%

-2245.3%

-2778.9%

-18599.8%

▼ >999 pts

Net margin

—

-2054.8%

-2248.8%

-16748.0%

▼ >999 pts

Return on assets (ROA)

—

-30.4%

-19.9%

-44.4%

▼ 24 pts

Return on equity (ROE)

—

-33.0%

-21.1%

-49.1%

▼ 28 pts

Free cash flow margin

-1336.4%

-4478.6%

-1585.2%

-2274.9%

-13829.1%

▼ >999 pts

Current ratio

24.86×

17.07×

13.87×

18.91×

10.49×

▼ 45%